Combination of three metals for the treatment of cancer: Gallium, rhenium and platinum. 1. Determination of the optimal schedule of treatment

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2769-2782

  Collery, Philippe ^a,b   Mohsen, Ahmed ^b   Kermagoret, Anthony ^c   D'Angelo, Jean ^c   Morgant, Georges ^c   Desmaele, Didier ^d   Tomas, Alain ^e   Collery, Thomas ^a   Wei, Ming ^f   Badawi, Abdelfattah ^g  

^a Polyclinic Maymard   (France)

^b Centre of Research and Development of Organometallic Compounds for Therapeutic Use   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIV PARIS SUD   (France)

^e CNRS   (France)

^f ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^g EGYPTIAN PETROLEUM RESEARCH INSTITUTE   (Egypt)

Author keywords

Breast cancer; Gallium; In vivo experiment; MCF 7; MCF 7 cells; Mice; Platinum; Rhenium; Therapeutic index

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DISELENO ETHER RHENIUM(1I)COMPLEX; GALLIUM; RHENIUM; TETRAKIS(1 OCTANOL)TRIS(5 AMINOSALICYLATE)GALLIUM(4); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SIZE; CELL STRAIN MCF 7; CHRONOTHERAPY; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; COORDINATION COMPLEXES; DRUG SYNERGISM; FEMALE; GALLIUM; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; RHENIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865676036     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (106)

1. Roy S, Westmaas JA, Hagen KD, van Wezel GP and Reedijk J: Platinum(II) compounds with chelating ligands based on pyridine and pyrimidine: DNA and protein binding studies. J Inorg Biochem 103: 1288-1297, 2009.
2. Leyland-Jones B, Bhalla RB, Farag F, Williams L, Coonley CJ and Warrell RP: Administration of gallium nitrate by continuous infusion: lack of chronic nephrotoxicity confirmed by studies of enzymuria and â2 microglobulinuria. Cancer Treat Rep 67: 941-942, 1983. (Pubitemid 14231387)
3. Warrell RP, Coonley CJ, Strauss DJ and Young CW: Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 51: 1982-1987, 1983. (Pubitemid 13092444)
4. Rasey JS, Nelson NJ and Larson SM: Relationship of iron metabolism to tumor cell toxicity of stable gallium salts. Int. J. Nucl Med Biol 8: 303-313, 1981. (Pubitemid 12162672)
5. Rasey JS, Nelson NJ and Larson SM: Tumor cell toxicity of stable gallium nitrate: enhancement by transferrin and protection by iron. Eur J Cancer Clin Oncol 18, 661-668, 1982. (Pubitemid 12057002)
6. Collery P, Millart H, Simoneau JP, Pluot M, Halpern S, Vistelle R, Lamiable D, Choisy H, Coudoux P and Etienne JC: Selective uptake of gallium administered orally, as chloride, by tumor cells. New Concepts In Cancer Chemotherapy. Spitzy KH, Karrer K (eds.). Proc 13th International Congress of Chemotherapy, Vienna part 284: PS 12-11, 35-43, 1983.
7. Collery P, Millart H, Simoneau JP, Pluot M, Halpern S, Pechery C, Choisy H and Etienne JC: Experimental treatment of mammary carcinomas by gallium chloride after oral administration: intratumor dosages of gallium, anatomopathologic study and intracellular micro-analysis. Trace Elem Med 1: 159-161, 1984. (Pubitemid 15187976)
8. Tajmir-Rihai HA, Naoui M and Ahmad RA: comparative study of calf-thymus DNA binding trivalent Al, Ga, Cr and Fe ions in aqueous solution. Metal Ions in Biology and Medicine. Anastassopoulou J, Collery P, Etienne JC, Theophanides T (eds.). John Libbey Eurotext, Paris 2: 98-101, 1992.
9. Chitambar CR, Matthaeus WG, Antholine WE, Graff K and O'Brien WJ: Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 72: 1930-1936, 1988. (Pubitemid 19030880)
10. Chitambar CR, Narasimhan J, Guy J, Sem DS and O'Brien WJ: Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res 51: 6199-6201, 1991.
11. Narasimhan J, Antholine WE and Chitambar CR: Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase. Biochem Pharmacol 44: 2403-2408, 1992. (Pubitemid 23005648)
12. Bara A, Guiet-Bara A, Durlach J and Collery P: Comparative effects of a carcinogenic (As) and an anticancer (Ga) metals on the transfer through the human amnion. Relationship with Mg. Ultrastructural and electrophysiological studies. Metal Ions in Biology and Medicine. Collery P, Poirier LA, Manfait M, Etienne JC (eds.). John Libbey Eurotext, Paris 1: 570-572, 1990.
13. Bara M, Guiet-Bara A, Collery P and Durlach J: Gallium action on the ionic transfer through the isolated human amnion. I. Effect on the amnion as a whole and interaction between gallium and magnesium: Trace Elem Med 2: 99-102, 1985. (Pubitemid 15228007)
14. Bara M, Guiet-Bara A, Collery P and Durlach J: Gallium action on the ionic transfer through the isolated human amnion. II. Effect on cellular and paracellular pathways. Trace Elem Med 9: 117-122, 1992.
15. Perchellet EM, Ladesich JB, Collery P and Perchellet JP: Microtubule-disrupting effects of gallium chloride in vitro. Anticancer Drugs 10: 477-488, 1999.
16. Gogvadze V, Zhukova A, Ivanov A, Khassanova L, Khassanova Z and Collery P: The effect of gallium on the calcium retention capacity of rat liver mitochondria. Metal Ions in Biology and Medicine, Collery P, Corbella J, Domingo JL, Etienne JC, Llobet JM (eds.). John Libbey Eurotext, Paris 4: 249-252, 1996.
17. Anghileri LJ and Robert J: Isomorphous ionic replacement: experimental evidence for the hypothesis proposed to explain Gallium-67 accumulation. J Nucl Med All Sc 26: 113-115, 1982.
18. Berggren MM, Burns LA, Abraham RT and Powis G: Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate. Cancer Res 53: 1862-1866, 1993. (Pubitemid 23127115)
19. Farzami B, Pournaki A, Collery P and Goliaei B: Effect of Gallium on the growth rate of U937 cell culture and the activity of tyrosine kinase. Metal Ions in Biology and Medicine, Khassanova LK, Collery P, Maymard I, Khassanova Z, Etienne JC (eds.). John Libbey Eurotext, Paris 7: 625-628, 2002.
20. Panagakos FS, Kumar E, Venescar C and Guidon P: The effect of gallium nitrate on synoviocyte MMP activity. Biochimie 82: 147-151, 2000. (Pubitemid 30153552)
21. Chen D, Frezza M, Shakya R, Cui QC, Milacic V, Verani CN and Dou QP: Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects. Cancer Res 67: 9258-9265, 2007. (Pubitemid 47535914)
22. Bockman RS, Guidon PT, Pan LC, Salvatori R and Kawaguchi A: Gallium nitrate increases type I collagen and fibronectin mRNA and collagen protein levels in bone and fibroblast cells. J Cell Biochem 52: 396-403, 1993. (Pubitemid 23258127)
23. Collery P, Millart H, Pluot M and Anghileri LJ: Effects of gallium chloride oral administration on transplanted C3HBA mammary adenocarcinoma: Ga, Mg, Ca and Fe concentration and anatomopathological characteristics. Anticancer Res 6: 1085-1087, 1986.
24. Yang M and Chitambar CR: Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med 45: 763-772, 2008.
25. Jakupec MA, Collery P and Keppler B: Synergistic antiproliferative effects of tris(8-quinolinolato) gallium(III) in combination with platinum drugs in ovarian and colon carcinoma cells. Metal Ions in Biology and Medicine. Collery P, Maymard I, Theophanides T, Khassanova L, Collery T, (eds.). John Libbey Eurotext, Paris 10: 110-115, 2008.
26. Collery P, Morel M, Millart H, Desoize B, Cossart C, Perdu D, Vallerand H, Bouana JC, Pechery C, Etienne JC, Choisy H and Dubois de Montreynaud JM: Oral administration of gallium in conjunction with platinum in lung cancer treatment. Metal Ions in Biology and Medicine. Collery P, Poirier LA, Manfait M, Etienne JC (eds.). John Libbey Eurotext, Paris 1: 437-442, 1990.
27. Collery P, Keppler B, Madoulet C and Desoize B: Gallium in cancer treatment. Crit Rev Oncol Hematol 42: 283-296, 2002. (Pubitemid 34615690)
28. Desoize B, Collery P, Akeli MG, Etienne JC and Keppler B: Tris(8-quinolinolato) Ga(III) is active against unicellular and multicellular resistance. Metal Ions in Biology and Medicine. Centeno J, Collery P, Vernet G, Finkelman RB, Gibb H, Etienne JC (eds.). John Libbey Eurotext, Paris 6: 573-576, 2000.
29. Collery P, Lechenault F, Cazabat A, Juvin E, Khassanova L, Evangelou A and Keppler B: Inhibitory effects of gallium chloride and tris (8-quinolinolato) gallium(III) on the proliferation of A 549 malignant cell lines. Anticancer Res 20: 955-958, 2000. (Pubitemid 30240659)
30. Collery P, Domingo JL and Keppler BK: Preclinical toxicology and gallium distribution of a new antitumour gallium compound: tris(8-quinolinolato) gallium (III). Anticancer Res 16: 687-692, 1996. (Pubitemid 126501648)
31. Collery P, Jakupec MA, Kynast B and Keppler BK: Preclinical and early clinical development of the oral Gallium complex KP 46 (FFC11). Metal Ions in Biology and Medicine. Alpoim MC, Morais PV, Santos MA, Cristovao A, Centeno JA, Collery P (eds.). John Libbey Eurotext, Paris 9: 521-524, 2006.
32. Valiahdi SM, Jakupec MA, Marculescu R and Keppler BK: Tris(8-quinolinolato)gallium(III) exerts strong antiproliferative effects in melanoma cells. Alpoim M, Morais PV, Santos MA, Cristovao AJ, Centeno JA, Collery P (eds.). John Libbey Eurotext, Paris 9: 282-286, 2006.
33. Bernstein LR, Tanner T, Godfrey C and Noll B: Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Metal Based Drugs 7: 33-47, 2000. (Pubitemid 30153561)
34. Chua MS, Bernstein LR, Li R and So SK: Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res 26: 1739-1743, 2006. (Pubitemid 43989426)
35. Ismail DA, Badawi AM, Collery P, Zakhary NI and Raouf AR: Antitumor effects of gallium(III) tris (salicylate)-ethanol on malignant cell lines and tumor bearing swiss albino-mice. Metal Ions in Biology and Medicine. Alpoim MC, Santos MA, Cristovao AJ, Centeno JA, Collery P, Morais PV (eds.). John Libbey Eurotext, Paris 9: 358-361, 2006.
36. Patrignani P, Santini G, Sciulli MG, Marinacci R, Fusco O, Spoletini L, Natoli C, Procopio A and Maclouf J: Cyclooxygenase-independent induction of p21WAF-1/CIP1, apoptosis and differentiation by L-745,337 and salicylate in HT-29 colon cancer cells. Adv Exp Med Biol 469: 555-561, 1999.
37. Law BK, Waltner-Law ME, Entingh AJ, Chytil A, Aakre ME, Norgaard P and Moses HL: Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. J Biol Chem 275: 38261-38267, 2000. (Pubitemid 32009146)
38. Nunez L, Valero RA, Senovilla L, Sanz-Blasco S, Garcia-Sancho J and Villalobos C: Cell proliferation depends on mitochondrial Ca2+ uptake: inhibition by salicylate. J Physiol 571: 57-73, 2006.
39. Santini G, Sciulli MG, Marinacci R, Fusco O, Spoletini L, Pace A, Ricciardulli A, Natoli C, Procopio A, Maclouf J and Patrignani P: Cyclooxygenase-independent induction of p21WAF-1/CIP1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells. Apoptosis 4: 151-162, 1999. (Pubitemid 29378783)
40. Seo MS, Oh SY, Park MJ, Kim SM, Kim MY, Han SI, Park HG and Kang HS: Implication of reactive oxygen species, ERK1/2, and p38MAPK in sodium salicylate-induced heat shock protein 72 expression in C6 glioma cells. Int J Mol Med 16: 841-849, 2005.
41. McDade TP, Perugini RA, Vittimberga FJ Jr., Carrigan RC and Callery MP: Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells. J Surg Res 83: 56-61, 1999. (Pubitemid 29394107)
42. Katerinaki E, Haycock J W, Lalla R, Carlson KE, Yang Y, Hill RP, Lorigan PC and MacNeil S: Sodium salicylate inhibits TNF-alpha-induced NF-kappaB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. Melanoma Res 16: 11-22, 2006. (Pubitemid 44133046)
43. Perugini RA, McDade TP, Vittimberga FJ Jr., Duffy AJ and Callery MP: Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines. J Gastrointest Surg 4: 24-32, discussion 32-33, 2000.
44. Shtivelband MI, Juneja HS, Lee S and Wu KK: Aspirin and salicylate inhibit colon cancer medium and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression. J Thromb Haemost 1: 2225-2233, 2003.
45. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R and Arthur HM: Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 20: 2009-2016, 2006. (Pubitemid 44953901)
46. Murono S, Yoshizaki T, Sato H, Takeshita H, Furukawa M and Pagano JS: Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res 60: 2555-2561, 2000. (Pubitemid 30262452)
47. Hyppolito MA, de Oliveira JA and Rossato M: Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur Arch Otorhinolaryngol 263: 798-803,2006. (Pubitemid 44127303)
48. Li G, Sha SH, Zotova E, Arezzo J, Van de Water T and Schacht J: Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 82: 585-596, 2002. (Pubitemid 34522371)
49. Soderberg LS, Barnett JB, Baker ML, Chang LW, Salari H and Sorenson JR: Copper(II)2(3,5-di-isopropylsalicylate)4 stimulates hemopoiesis in normal and irradiated mice. Exp Hematol 16: 577-580, 1988.
50. McCarty MF, and Block KI: Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy. Integr Cancer Ther 5: 252-268, 2006.
51. Ye QS, Lou LG, Liu WP, Yu Y, Chen XZ, Hou SQ, Gao WQ and Liu Y: Synthesis and in vitro cytotoxicity of novel lipophilic (diamine) platinum (II) complexes of salicylate derivatives. Bioorg Med Chem Lett 17: 2146-2149,2007. (Pubitemid 46484314)
52. Illan-Cabeza NA, Garcia-Garcia AR, Moreno-Carretero MN, Martinez-Martos JM and Ramirez-Exposito MJ: Synthesis, characterization and antiproliferative behavior of tricarbonyl complexes of rhenium(I) with some 6-amino-5- nitrosouracil derivatives: crystal structure of fac-[ReCl(CO)3 (DANU-N5,O4)] (DANU=6-amino-1,3-dimethyl-5-nitrosouracil). J Inorg Biochem 99: 1637-1645, 2005. (Pubitemid 41043187)
53. Shtemenko AV, Collery P, Shtemenko NI, Domasevitch KV, Zabitskaya ED and Golichenko AA: Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin. Dalton Trans 26: 5132-5136, 2009.
54. Shtemenko A, Shtemenko N, Oliynyk SA and Zelenuk MA: Lyposome forms of rhenium cluster compounds in models of haemolytic anemia. Metal Ions in Biology and Medicine. Khassanova L, Collery P, Maymard I, Khassanova Z, Etienne JC (eds.). John Libbey Eurotext, Paris 7: 558-561, 2002.
55. Collery P, Shtemenko N, Shtemenko A, Bourleaud M, Etienne JC, Maymard I and Loriquet P: Supplementation by rhenium compounds instead of iron compounds during the treatment by erythropoietin of anemia in cancer patients. Metal Ions in Biology and Medicine. Cser MA, Sziklai-Laszlo I, Etienne JC, Maymard I, Centeno J, Khassanova L, Collery P (eds.). John Libbey Eurotext, Paris 8: 534-537, 2004.
56. Shtemenko N, Collery P, and Shtemenko A: Synergistic effect of cisplatin and cis-rhenium(III) diadamantate on tumor growth. Metal Ions in Biology and Medicine. Alpoim MC, Morais PV, Santos MA, Cristovao AJ, Centeno JA, Collery P (eds.). John Libbey Eurotext, Paris 9: 374-381, 2006.
57. Shtemenko N, Collery P and Shtemenko A: Dichlorotetramu- Isobutyratodirhenium (III): enhancement of cisplatin action and RBC-stabilizing properties. Anticancer Research 27: 2487-2492, 2007. (Pubitemid 47228093)
58. Kermagoret A, Morgant G, D'Angelo J, Tomas A, Roussel P, Bastian G, Collery P and Desmaële D: Synthesis, structural characterization and biological activity against several human tumor cell lines of four rhenium(I) diseleno-ethers complexes: Re(CO)3Cl(PhSe(CH2)2SePh), Re(CO)3Cl (PhSe(CH2)3SePh), Re(CO)3Cl(HO2C-CH2Se(CH2)2SeCH2-CO2H) and Re(CO)3Cl (HO2C-CH2Se(CH2)3SeCH2-CO2H). Polyhedron 30: 347-354, 2011.
59. Collery P, Lechenault F, Juvin E, Khassanova L, and Cazabat A: Delayed inhibitory effects of gallium chloride on U937 malignant cell lines. Anticancer Res 17: 4072, 1997.
60. Collery P, Millart H, Lamiable D, Vistelle R, Rinjard P, Tran G, Gourdier B, Cossart C, Bouana JC and Pechery C: Clinical pharmacology of gallium chloride after oral administration in lung cancer patients. Anticancer Res 9: 353-356, 1989. (Pubitemid 19174638)
61. Collery P, Millart H, Pourny C, Choisy H and Etienne JC: Pharmacokinetics of gallium after oral administration. Proc. IUPHAR 9th International Congress of Pharmacology, London, abstract 501, 1984.
62. Hata Y, Sandler A, Loehrer PJ, Sledge GW Jr. and Weber G: Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency. Oncol Res 6: 19-24, 1994.
63. Chitambar C, Zivkovic Z and Abrams R: Effect of gallium on hemoglobin production. Proc ASCO 5: 44, 1986.
64. Chitambar CR and Narasimhan J: Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res 51: 6199-6201, 1991.
65. Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B and Cavallin-Stahl E: Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol 37: 23-31, 1995.
66. Fulco RA, Vannozzi M, Collecchi P, Merlo F, Parodi B, Civalleri D and Esposito M: Effect of normal saline on cisplatin pharmacokinetics and antitumor activity in mice bearing P388 leukemia. Anticancer Res 10: 1603-1610, 1990.
67. Prasad SB and Khynriam D: Cisplatin-induced changes in tissue glutathione level and glutathione-related enzymes in Dalton's lymphoma-bearing mice. Metal Ions in Biology and Medicine. Cser MA, Sziklai-Laszlo I, Etienne JC, Maymard I, Centeno J, Khassanova L, Collery P (eds.). John Libbey Eurotext, Paris 8: 368-372, 2004.
68. Vistelle R, Collery P and Millart H: In vivo distribution of gallium in healthy rats after oral administration and interactions with iron, magnesium and calcium. Trace Elem Med 6: 27-32, 1989. (Pubitemid 19068979)
69. Collery P, Millart H, Choisy H, Blanchot G, Leroy A and Anghileri LJ: Dose-effect of GaCl3, orally administered, on gallium, magnesium, calcium and iron concentrations in tumour and kidneys of mammary adenocarcinoma-bearing mice. Anticancer Res 12: 1920-1921, 1992.
70. Collery P, Kleisbauer JP, Robinet G, Paillotin D, Arnaud A, Balmes P, Poirier R, Claeyssens S, Prevost A, Millart H, Morel M, Blanchot G and Leroy A: Management of platinum and gallium therapies in lung cancer patients. Metal Ions in Biology and Medicine, Collery P, Poirier L, Littlefield N, Etienne JC (eds.). John Libbey Eurotext, Paris 3: 335-342, 1994.
71. Collery P, Millart H, Morel M, Desoize B, Choisy H and Pechery C. Gallium-potentiation of cancer chemotherapy. Handbook on Metal-Ligand Interactions in Biological Fluids 2: Part 5, Chapter 4, Section E, 1-8, 1994.
72. Collery P, Morel M, Desoize B, Millart H, Perdu D, Prevost A, Vallerand H, Pechery C, Choisy H, Etienne JC and Dubois De Montreynaud JM: Combination chemotherapy with cisplatin, etoposide and gallium chloride for lung cancer: individual adaptation of doses. Anticancer Res 11: 1529-1531, 1991.
73. Collery P, Millart H, Kleisbauer JP, Paillotin D, Robinet G, Durand A, Clayessen S, Legendre JM, Leroy A, Rousseau A, Pechery C and Kochmans S: Dose optimization of gallium chloride, orally administered, in combination with platinum compounds. Anticancer Res 14: 2299-2306, 1994.
74. Collery P, Morel M, Millart H, Perdu D, Lavaud F, Anghileri LJ, Pluot M, Choisy H and Pechery C: Relationship between intratumoral gallium concentration and tumor mass, after oral administration of gallium chloride. Metal Ions in Biology and Medicine. Collery P, Poirier LA, Manfait M, Etienne JC (eds.). John Libbey Eurotext, Paris 3: 331-334, 1994.
75. Collery P, Millart H, Lamiable D, Vistelle R, Berthier A, Betbeze P, Cossart C, Mulette T, Masure F, Gourdier B et al: Magnesium alterations and pharmacokinetic data in gallium-treated lung cancer patients. Magnesium 8: 56-64, 1989. (Pubitemid 19141532)
76. Collery P, Millart H, Ferrand O, Jouet JB, Dubois JP, Barthes G, Pourny C, Pechery C, Choisy H, Cattan A, Dubois de Montreynaud JM and Etienne JC: Gallium chloride treatment of cancer patients after oral administration: a pilot study. Chemotherapia 4: 1165-1166, 1985.
77. Collery P, Lechenault F, Cazabat A, Juvin E, Khassanova L, Evangelou A and Keppler B: Inhibitory effects of gallium chloride and tris (8-quinolinolato)gallium(III) on A549 human malignant cell line. Anticancer Res 20: 955-958, 2000. (Pubitemid 30240659)
78. Thiel M, Schilling T, Gey DC, Ziegler R, Collery P and Keppler BK: tris(8-quinolinolato)gallium(III), a novel orally applied antitumor gallium compound. Relevance of tumor models for anticancer drug development. Contributions to Oncology. Fiebig HH, Burger AM (eds.). Karger, Basel 54: 439-443, 1999.
79. Chitambar CR, Purpi DP, Woodliff J, Yang M and Wereley JP: Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J Pharmacol Exp Ther 322: 1228-1236, 2007. (Pubitemid 47295794)
80. Chitambar CR and Purpi DP: A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells. Leuk Res 34: 950-953, 2010.
81. Arnold C, Chaffin MK, Cohen N, Fajt VR, Taylor RJ and Bernstein LR: Pharmacokinetics of gallium maltolate after intragastric administration in adult horses. Am J Vet Res 71: 1371-1376, 2010.
82. Martens RJ, Mealey K, Cohen ND, Harrington JR, Chaffin MK, Taylor RJ and Bernstein LR: Pharmacokinetics of gallium maltolate after intragastric administration in neonatal foals. Am J Vet Res 68: 1041-1044, 2007. (Pubitemid 47616613)
83. Lee EJ, Park HG and Kang HS: Sodium salicylate induces apoptosis in HCT116 colorectal cancer cells through activation of p38MAPK. Int J Oncol 23: 503-508, 2003.
84. Ordan O, Rotem R, Jaspers I and Flescher E: Stress-responsive JNK mitogen-activated protein kinase mediates aspirin-induced suppression of B16 melanoma cellular proliferation. Br J Pharmacol 138: 1156-1162, 2003. (Pubitemid 36459838)
85. Hernandez M, de Arriba AF, Merlos M, Fuentes L, Crespo MS and Nieto ML: Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells. Br J Pharmacol 132: 547-555, 2001. (Pubitemid 32142368)
86. Ghezzo F, Cesano L, Mognetti B, Pesce E, Pirro E, Corvetti G, Berta GN, Zingaro B and Di Carlo F: Salicylate inhibition of rat mammary carcinogenesis and angiogenesis in female rat compatible with misoprostol administration. Int J Oncol 26: 697-702, 2005.
87. Drew JE, Padidar S, Horgan G, Duthie GG, Russell WR, Reid M, Duncan G and Rucklidge GJ: Salicylate modulates oxidative stress in the rat colon: a proteomic approach. Biochem Pharmacol 72: 204-216, 2006. (Pubitemid 43850432)
88. Chung YM, Bae YS and Lee SY: Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. Free Radic Biol Med 34: 434-442, 2003. (Pubitemid 36140168)
89. Blincoe C, Chidambaram M, Salari H, Bond KB, Evans DT, Gray-Kaufman RA, Griffey HB, Tranby SG, Garner-Johnson B, Lee T and Sorenson JR: Pharmacokinetic distribution of 67Cu (II)2[3,5-di-isopropyl(carboxy-14C)salicylate] 4 among murine tissues. Curr Med Chem 11: 3007-3015, 2004. (Pubitemid 39369269)
90. Viola-Villegas N, Rabideau AE, Cesnavicious J, Zubieta J and Doyle RP: Targeting the folate receptor (FR): imaging and cytotoxicity of ReI conjugates in FR-overexpressing cancer cells. Chem Med Chem 3: 1387-1394, 2008.
91. Desbouis D, Struthers H, Spiwok V, Kuster T and Schibli R: Synthesis, in vitro, and in silico evaluation of organometallic technetium and rhenium thymidine complexes with retained substrate activity toward human thymidine kinase type 1. J Med Chem 51: 6689-6698, 2008.
92. Struthers H, Hagenbach A, Abram U and Schibli R: Organometallic [Re(CO)3]+ and [Re(CO)2(NO)]2+ labeled substrates for human thymidine kinase 1. Inorg Chem 48: 5154-5163, 2009.
93. Bartholoma MD, Vortherms AR, Hillier S, Ploier B, Joyal J, Babich J, Doyle RP and Zubieta J: Synthesis, cytotoxicity, and insight into the mode of action of Re(CO)3 thymidine complexes. Chem Med Chem 5: 1513-1529, 2010.
94. Bowen ML, Chen ZF, Roos AM, Misri R, Hafeli U, Adam MJ and Orvig C: Long-chain rhenium and technetium glucosamine conjugates. Dalton Trans 42: 9228-9236, 2009.
95. Choi SJ, Brylev KA, Xu JZ, Mironov YV, Fedorov VE, Sohn YS, Kim SJ and Choy HJ: Cellular uptake and cytotoxicity of octahedral rhenium cluster complexes. J Inorg Biochem 102: 1991-1996, 2008.
96. Martinez-Lillo J, Mastropietro TF, Lappano R, Madeo A, Alberto ME, Russo N, Maggiolini M and De Munno G: Rhenium(IV) compounds inducing apoptosis in cancer cells. Chem Commun (Camb) 47: 5283-5285, 2011.
97. Fricker SP: Cysteine proteases as targets for metal-based drugs. Metallomics 2: 366-377, 2010.
98. Wirth S, Wallek AU, Zernickel A, Feil F, Sztiller-Sikorska M, Lesiak-Mieczkowska K, Brauchle C, Lorenz IP and Czyz M: Tautomerization of 2-nitroso- N -arylanilines by coordination as N,N′-chelate ligands to rhenium(I) complexes and the anticancer activity of newly synthesized oximine rhenium(I) complexes against human melanoma and leukemia cells in vitro. J Inorg Biochem 104: 774-789, 2010.
99. Vucina J and Han R: Production and therapeutic use of rhenium-186, 188, the future of radionuclides. Med Pregl 56: 362-365, 2003.
100. Scheffler J, Derejko M, Bandurski T and Romanowicz G. Application of rhenium-188 HEDP in bone metastases therapy. Nucl Med Rev Cent East Eur 6: 55-57, 2003. (Pubitemid 36722590)
101. Hindorf C, Flux GD, Ibisch C, and F, Kraeber Bodere: Clinical dosimetry in the treatment of bone tumors: old and new agents. Q J Nucl Med Mol Imaging 55: 198-204, 2011.
102. Cheng A, Chen S, Zhang Y, Yin D, and Dong M: The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases. Cancer Biother Radiopharm 26: 237-244, 2011.
103. Li S, Liu J, Zhang H, Tian M, Wang J and Zheng X: Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 26: 919-922, 2001. (Pubitemid 33020333)
104. Liepe K, Geidel HH, Bergmann R, Haase M, Runge R and Kotzerke J: Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer. Nucl Med Commun 30: 693-699, 2009.
105. Isakoff SJ: Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 16: 53-61, 2010.
106. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer current status and future directions. Ann Oncol 20: 1913-1927, 2009.